Age, Biography and Wiki
Olivier Brandicourt was born on 13 February, 1956 in Casablanca, Morocco, is a French businessman. Discover Olivier Brandicourt's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 68 years old?
| Popular As |
N/A |
| Occupation |
Business executive |
| Age |
68 years old |
| Zodiac Sign |
Aquarius |
| Born |
13 February, 1956 |
| Birthday |
13 February |
| Birthplace |
Casablanca, Morocco |
| Nationality |
France
|
We recommend you to check the complete list of Famous People born on 13 February.
He is a member of famous Business executive with the age 68 years old group.
Olivier Brandicourt Height, Weight & Measurements
At 68 years old, Olivier Brandicourt height not available right now. We will update Olivier Brandicourt's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Olivier Brandicourt Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Olivier Brandicourt worth at the age of 68 years old? Olivier Brandicourt’s income source is mostly from being a successful Business executive. He is from France. We have estimated Olivier Brandicourt's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
Business executive |
Olivier Brandicourt Social Network
Timeline
Olivier Brandicourt (born 13 February 1956) is a French business executive and physician, and the former chief executive officer of Sanofi.
Brandicourt studied medicine in Paris and specialized in infectious diseases and tropical medicine.
He spent eight years with the Institute of Infectious and Tropical Diseases of the Pitié-Salpêtrière Hospital in Paris, where he focused on malaria research in West and Central Africa.
Prior to that, he spent two years in the Republic of the Congo as a doctor.
He holds an advanced degree in Cellular and Immunological Pathophysiology from Paris Descartes University and a master's degree in biology from University of Paris XII.
Brandicourt joined Pfizer in 2000, after its acquisition of Warner-Lambert/Parke-Davis, where he started his career, first in Medical Affairs and later in Marketing and Management.
He spent 12 years at Pfizer Inc. where he held several senior positions across a range of disciplines, including President and General Manager of the Global Specialty Care and Primary Care businesses, and later as president and General Manager of the Primary Care Business Unit.
He served as a member of the executive leadership team of Pfizer Inc. and oversaw the introduction of the cholesterol treatment Lipitor.
In 2007, he was the supervisor of the failed launch of the Exubera.
From 2013 to 2015, he was chief executive officer and chairman of the board of management of Bayer HealthCare AG, where he was responsible for leading the company's healthcare portfolio globally, encompassing pharmaceuticals, consumer care, animal health and medical care businesses.
In February 2015, Olivier Brandicourt was appointed as the chief executive officer of Sanofi.
His golden handshake of US$4.5 million upon taking on the appointment was criticized by French Ministers Stéphane Le Foll and Ségolène Royal.
In November 2015, Sanofi announced its 2020 Strategic Plan that implies reshaping its activities into 3 portfolios: Diabetes, cardiovascular, and vaccines.
In May 2016, Olivier Brandicourt announced a reshuffle in the company's management, in line with the 2020 Strategic Plan.
In January 2017, Sanofi completed an asset swap of its animal health business, Merial, for Boehringer's consumer healthcare business, CHC.
Subsequently, Sanofi launched a fifth Global Business Unit for Consumer Health Care.
